期刊文献+

中药辨证论治联合介入及索拉非尼对H22肝癌荷瘤小鼠疗效的实验研究 被引量:9

Efficacy of TCM differential treatment combined interposition and sorafenib on H22 hepatocarcinoma mice
下载PDF
导出
摘要 目的:比较与评价H22肝癌小鼠单纯西医及中西医联合治疗方案的疗效。方法:采用H22腋下实体瘤昆明种雄性小鼠,应用小鼠标准化、计量化辨证方法,观察复合化疗制剂肿瘤局部注射联合索拉非尼口服、单纯西医治疗方案,及其西医治疗方案联合中药辨证论治方案对小鼠带瘤生存时间、抑瘤率和证候的疗效。结果:3种治疗方案均有一定的抑瘤作用,而中西医结合辨证论治方案较单纯西医方案在小鼠带瘤生存时间、对气血阴阳证候的影响,以及胸腺和脾脏重量等方面,具有一定的优势。结论:中西医结合辨证论治原发性肝癌的治疗方案较单纯西医治疗方案具有一定的优势。 Objective:To assess the efficacy of simple western medicine(WM) and wm combined traditional Chinese medicine(TCM) for treating H22 hepatocarcinoma mice.Methods:Observed male Kunming mice with tumor survival,inhibition rate and symptoms in order to estimate therapeutic effects of tumor local compound chemotherapy and sorafenib oral administration,as well as which of pure wm combined TCM differential treatment,by standardized and quantitative of syndrome differentiation methods.Results:All three therapies had a certain inhibitory effect,which wm combined TCM possessed certain superiority in survival time,the impact to the syndrome of Qi,blood,Yin,Yang,and thymus and spleen weight.Conclusion:wm Combined TCM have certain advantage than simple wm for treating H22 hepatocarcinoma mice.
出处 《中西医结合肝病杂志》 2012年第1期34-37,共4页 Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
基金 上海市教委学科建设项目 国家科技重大专项课题(No.2009ZX09502-018)
关键词 肝癌 小鼠 辨证论治 介入/治疗 索拉非尼/药理作用 疗效评价 hepatocarcinoma mice differential treatment interposition therapy sorafenib/pharmacological effect assess therapeutic effect
  • 相关文献

参考文献5

  • 1方肇勤,潘志强,卢文丽,刘小美,侯俐,廖明娟.大鼠、小鼠常见证候计量化辨证方法的建立及其评价[J].中国中医基础医学杂志,2007,13(7):502-505. 被引量:101
  • 2方肇勤.大鼠/小鼠实验辨证论治方法学[M].北京:科学出版社,2009:56-86.
  • 3STRUMBERG D, RIEHLY H, HILGER RA, et al. Phasel clinical and pharmaeokinetie study of the novel Raf kinase and vaseular endothelial growth factor receptor inhibitor BAY43-9006 in Patients with advanced refractory solid tumors [ J ] . J Clin Oncol, 2005, 23 (5) : 965 - 972.
  • 4BRUIX J, CHENG A, Y KANG, et al. Effect of macroscopic vascular invasion (MVI) , extrahepatie spread (EHS), and ECOGperformance status (ECOGPS) on outcome in patients with advanced hepatocellular carcinoma ( HCC ) treated with sorafenib : Analysis of two phase Ⅲ, randomized, double-blind trials [ J ] . J Clin Oncol, 2009, 27 (15) : 4580.
  • 5陈德溯,方肇勤.中药治疗原发性肝癌中晚期的药味频率分析[J].辽宁中医杂志,2002,29(4):187-189. 被引量:50

二级参考文献34

共引文献151

同被引文献165

引证文献9

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部